Fulranumab

A4DAB121 | Neurological disorders | Phase-III
NGFB
G2 / IgG2
Janssen Pharmaceuticals Janssen Research & Development Takeda Amgen
Phase-III
Whole mAb
AMG-403 AMG403 JNJ-42160443 JNJ42160443
—
IMGT PubChem (135329083) PubChem (160677291) PubChem (310264744) PubChem (347911282) PubChem (472220005) PubChem (472423438) PubChem (472439118) PubChem (472441267) PubChem (481155491) PubChem (505603426) Thera-SAbDab YAbS
Avg A4D Score
-0.6875
Score Range
-0.69
Structures
1
Avg. A4D Score per Structure
pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2

Structure ID Source PDB Seq. Identity Avg. A4D Score pH (Min Agg.) pH (Max Agg.) Score CDR Score non-CDR
A4DAB121_4m6o_H_L 4m6o 100% -0.6875 6.5 9.0 -0.3464 -0.7315